Brain Cancer

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

CNS Pharmaceuticals has acquired the orphan drug designations for TPI 287 in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

The B7-H3–directed CAR T-cell therapy BCB-276 received RMAT designation for the treatment of patients with diffuse intrinsic pontine glioma.

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.

The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

The FDA issued a complete response letter to the new drug application seeking the approval of TLX101-CDx as an imaging agent for glioma.

The FDA granted breakthrough therapy designation to BCB-276 for pediatric diffuse intrinsic pontine glioma.

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

The ZEISS INTRABEM 700 platform received 510(k) clearance from the FDA for use in neuro-oncology and breast cancer surgery.

William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.

The combination of VXM01 and avelumab was well tolerated and has the potential to generate clinically meaningful responses in recurrent glioblastoma.

NEO100 was given rare pediatric disease designation by the FDA for the treatment of patients with pediatric-type diffuse high-grade glioma.

Georges Ayoub, MD, MS, discusses how a supervised deep-learning model trained with expert-labeled data seeks to improve interpretability and diagnostic precision in glioblastoma morphological analysis.

A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.

Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.

Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Drs Camidge and Boire discuss Dr Boire's path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.